Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

SKI 606 - Bosutinib

CAS 380843-75-4

C26H29Cl2N5O3  MW 530.446

Purity: 99%

Soluble in DMSO

Ordering Information:

Cat. No. Axon 1407   

Qty1: 5 mg (research sample) / inquire

Qty2: 25 mg (research sample) / inquire

Qty3: on request contract research synthesis

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for our product range and services.

Biological Activity:   A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL).   References: online 1, 2, 3, 4   A Vultur et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008, 7(5), 1185–94. [online]   W. A. Messersmith et al.Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clinical Oncol. 2007, 25 (18S), 3552. (ASCO Annual Meeting Proceedings Part I.)   JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol. 2008, 119, 212-217. [online]     Chemical Name: 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinoline-3-carbonitrile

SKI 606 - Bosutinib | Bcr-Abl & Src inhibitor | Axon Medchem | Axon 1407 | SKI606

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.